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International Circumpolar Surveillance (ICS) is a population-based surveillance system for invasive bacterial 
diseases established in the U.S. Arctic, Northern Canada, Greenland, Iceland, Norway, Finland, and Northern 
Sweden.  Data collection began in 1999 and includes information on disease caused by Streptococcus 
pneumoniae, Haemophilus influenzae, Neisseria meningitidis, and groups A and B Streptococcus (GAS, GBS).  
This report reviews the data collected for the year 2005. 
 
Data on invasive disease with the organism S. pneumoniae are collected from all participating countries.  A total 
of 1,987 cases of invasive pneumococcal disease were identified in 2005.  Overall, rates of invasive S. 
pneumoniae were highest in individuals less than 2 years of age except in Greenland where rates were highest in 
persons 65 years and older.  Case fatality ratios ranged from 5-25%.  Race and ethnicity data are collected only 
in N. Canada and the U.S. Arctic; rates of invasive pneumococcal disease in Northern Canadian Aboriginals 
and U.S. Arctic Native populations were 20 and 47 cases per 100,000 population, respectively, which represents 
a decrease in disease from 2004 in Northern Canadian Aboriginal people and an increase in disease in U.S. 
Arctic Native people.  Pneumonia with bacteremia and bacteremia were the most common clinical presentations 
for invasive disease; cigarette smoking and alcohol abuse were the most common risk factors.  The most 
common S. pneumoniae serotype in Finland and Iceland is 14; in Greenland the most common serotype is 22F, 
in the U.S. Arctic the most common serotype is 19A; and in N. Canada the most common serotypes are 1 and 3. 
 
Data on invasive disease due to H. influenzae, N. meningitidis, GAS and GBS are currently collected in 
Greenland, Northern Canada, Northern Sweden and the U.S. Arctic; Norway began contributing data on cases 
of N. meningitidis in 2005.  A total of 22 H. influenzae cases, 42 N. meningitidis cases, 55 GAS cases, and 36 
GBS cases were reported in 2005.  In general, the highest rates of disease as a result of all organisms occurred 
in N. Canada Aboriginal or Alaska Native persons less than two years of age. 
 













Finland 735 (14) N/A N/A N/A N/A 
Greenland 17 (29.8) 0 (0) 1 (1.8) 1 (1.8) 0 (0) 
Iceland 38 (12.8) N/A N/A N/A N/A 
N. Canada 23 (17.3) 11 (8.3) 1 (0.8) 14 (10.5) 1 (0.8) 
N. Sweden 23 (9.1) 2 (0.8) 0 (0) 4 (1.6) 11 (4.4) 
Norway 1,029 (22.3) N/A 37 (0.8) N/A N/A 
U.S. Arctic 122 (18.4) 9 (1.4) 3 (0.5) 36 (5.4) 24 (3.6) 
Total 1,987 (17.6) 22 (2) 42 (0.7) 55 (5) 36 (3.3) 






In January, 1999, the United States and Canada began international cooperative population-based surveillance 
for invasive S. pneumoniae by all laboratories serving residents of the North American Arctic.  In January, 
2000, this surveillance system expanded to include invasive diseases with the following organisms:  H. 
influenzae (all types), N. meningitidis, GAS, and GBS.  These pathogens were selected for ICS because rates of 
these diseases are elevated in indigenous peoples of the north, strains demonstrate resistance to commonly used 
antibiotics, they are routinely cultured in clinical laboratories, and clinically important serotypes of S. 
pneumoniae, H. influenzae, and N. meningitidis are vaccine preventable in infants and adults. 
 
Denmark’s autonomous region of Greenland joined ICS in 2000; Iceland, Norway (including Svalbard), and 
Finland joined in 2001; and Northern Sweden joined in 2003.  This report contains year 2005 data on all five 
surveillance organisms from Greenland, Northern Canada, Northern Sweden, and the U.S. Arctic, N. 
meningitidis and S. pneumoniae data from Norway, and S. pneumoniae data from Finland and Iceland. 
 
GOALS  
The goal of ICS is to establish an integrated network of hospital and public health facilities throughout the 
Arctic countries to monitor infectious diseases of concern.  Linking public health facilities within Arctic nations 
will allow for the collection and sharing of uniform laboratory and epidemiological data that will describe the 
prevalence of infectious diseases in Arctic populations and assist in the formulation of prevention and control 
strategies. 
 
The project, initiated in 1998, focused on establishing an ICS system for diseases caused by S. pneumoniae.  S. 
pneumoniae causes pneumonia, meningitis, and bacteremia in both the very young and the elderly.  Once easily 
treated with antibiotics, S. pneumoniae is now becoming resistant to commonly used antibiotics.  This is of 
great concern to the public health community and is increasingly a target for surveillance by many countries 
worldwide.  A polysaccharide vaccine is available for use in persons two years of age and older.  A conjugate 
vaccine for infants has been developed and is licensed for use in the U.S., Canada, and the European Union.  
The fact that diseases caused by S. pneumoniae were already being monitored by many public health authorities 
within the Arctic states made establishing a circumpolar surveillance system for this infection feasible.  In 
addition, due to the availability of polysaccharide and conjugate vaccines, much of the morbidity and mortality 
caused by S. pneumoniae is currently preventable. 
 
ICS objectives include: 
  Identify key public health contacts within Arctic countries.  These persons should be familiar with infectious 
disease surveillance systems in place (particularly surveillance systems for diseases caused by S. 
pneumoniae) in the member country.  Through correspondence and working group meetings, the scope and 
gaps of the surveillance systems are determined. 
  Determine the comparability of laboratory and data collection methods, and negotiate standard protocols 
and quality control programs. 
  Share and report data in agreed upon formats. 
  Form a working group of key laboratory and public health contacts to coordinate pneumococcal surveillance 
within their respective jurisdictions.  This group meets on a regular basis to review problems, progress, 
compliance, report generation, and future plans. 
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  Form a steering committee of national Arctic health experts to coordinate new objectives and initiatives 
within ICS. 
 
This program forms a framework through which surveillance of other infectious diseases as well as prevention 
and control programs can be added.  Other infectious diseases of circumpolar community concern include:  
other invasive bacterial diseases (caused by H. influenzae, N. meningitidis, GAS, and GBS), tuberculosis, HIV, 
hepatitis, foodborne diseases (botulism, brucellosis), waterborne diseases, respiratory diseases of children such 
as those caused by respiratory syncytial virus, and chronic conditions related to infectious agents (hepatitis B 
virus and liver cancer, human papilloma virus and cervical cancer).  In addition, the surveillance model 
developed by this program for infectious disease may be adapted to monitor other non-infectious human health 
priorities of community concern. 
 
METHODS  
ICS is coordinated by personnel at the Arctic Investigations Program, Centers for Disease Control and 
Prevention, in Anchorage, Alaska. 
 
A case of invasive S. pneumoniae, H. influenzae, N. meningitidis, GAS or GBS is defined by the isolation of the 
bacteria from a normally sterile site, (including blood, cerebrospinal fluid, pleural fluid, peritoneal fluid or joint 
fluid) that has been taken from a resident of the surveillance area. 
 
In the U.S. Arctic and Northern Canada, laboratory, demographic and clinical data are collected continually by 
ICS, while in Greenland, Iceland, Northern Sweden, Norway, and Finland, summary data are submitted to ICS 
in aggregate at the end of the year. 
 
Surveillance System Description by Country/Region 
 
The following table outlines the organisms reported and data provided by each country or region. 
 











































Finland X     X X    
Greenland X X X X X X X   X 
Iceland X     X X   X 
N. Canada X X X X X X X X X X 
N. Sweden X X     X    
Norway X  X    X   X 






  23 district hospital laboratories participate in ICS. o Provide diagnostic microbiology services for all residents of Finland. o All invasive isolates of S. pneumoniae submitted to the National Public Health Institute (KTL) 
laboratory in Oulu. 
  Antimicrobial susceptibility testing of S. pneumoniae isolates is performed by agar dilution method at 
district hospital laboratories as well as the KTL laboratory. 
  Serotyping is performed at the KTL laboratory by counter-immune-electrophoresis. 
  Population estimates for 2005 were obtained from the website http://www.stat.fi 
 
Greenland 
  15 district hospital laboratories participate in ICS. o Provides diagnostic microbiology services for all residents of Greenland. o All invasive isolates of S. pneumoniae, H. influenzae, N. meningitidis, GAS, and GBS are submitted to 
reference laboratories in Nuuk and Copenhagen. 
  Antimicrobial susceptibility testing of S. pneumoniae isolates is performed by agar dilution at the central 
laboratory at Queen Ingrid’s Hospital in Nuuk. 
  Serotyping is performed at the Statens Serum Institute in Copenhagen, Denmark, by the Quellung method. 
  Clinical and demographic data for every case of invasive S. pneumoniae, H. influenzae, N. meningitidis, 
GAS, and GBS was collected by public health authorities at the end of the year and entered onto a 
standardized collection tool, the Bacterial Diseases Surveillance Form (BDSF), which is also used in 
Iceland, Northern Canada, and the U.S. Arctic. 
  Population estimates for 2005 were obtained from the website http://www.statgreen.gl 
 
Iceland 
  10 district hospital laboratories and one regional laboratory participate in ICS. o Provide diagnostic microbiology services for all residents of Iceland. o All invasive isolates of S. pneumoniae submitted to the reference hospital in Reykjavik. 
  Antimicrobial susceptibility testing of S. pneumoniae isolates is performed by disc diffusion method at the 
Landspitali University Hospital (LUH) in Reykjavik and the laboratory at the regional hospital in Akureyri.  
All oxacillin resistant isolates are then analyzed by E test. 
  Serotyping is performed at the LUH by coagglutination using antisera from Statens Serum Institute. 
  Clinical and demographic data for every case of invasive S. pneumoniae was collected by public health 
authorities at the end of the year and entered onto the same collection form (BDSF) used in Greenland, 




 Population estimates for 2005 were obtained form the website http://www.hagstofa.is 
 
Northern Canada 
  14 Canadian laboratories participate in ICS. o Provide diagnostic microbiology services for all residents of the Yukon Territory, Northwest Territories, 
Nunavut, Northern Quebec, and Northern Laborador. o Submit all invasive isolates of S. pneumoniae, H. influenzae, N. meningitidis, GAS, and GBS to one of 
two reference laboratories in Canada. o S. pneumoniae, H. influenzae, GAS, and GBS isolates are serotyped by the Quellung method using 
Statens Serum Institute antisera. 
  Antimicrobial susceptibility of S. pneumoniae, GAS, and GBS isolates was tested by micro-broth dilution 
(according to NCCLS recommendations). 
  Communicable disease consultants located within one of the five regions of Northern Canada provided 
clinical and demographic information on the same collection form (BDSF) used in Greenland, Iceland, and 
the U.S. Arctic. 
  Laboratory and clinical data are forwarded to the ICS coordinator at AIP in Anchorage. 
  Population estimates for 2005 were obtained from the website http://www.statcan.ca 
 
Northern Sweden 
  1 district laboratory participates in ICS. o Provides diagnostic microbiology services for all residents of Norrbotten County o The main reference laboratory is at the Swedish Institute for Infectious Disease Control in Stockholm. o Isolates are serotyped by the Quellung method. 
 Antimicrobial susceptibility testing was by disc diffusion at the University Hospital in Umea and Sunderby 
Hospital in Lulea. 
  Population estimates for 2005 were obtained from the website http://www.scb.se/default____2154.asp 
 
Norway 
  33 district hospital laboratories participate in ICS. o Provide diagnostic microbiology services for all residents of Norway. o All invasive isolates of S. pneumoniae submitted to one of two reference laboratories in Oslo or Tromso. 
  Antimicrobial susceptibility testing of S. pneumoniae isolates is performed using the disc diffusion method 
at district hospital laboratories, the reference laboratory in Tromso or the main national laboratory in Oslo. 
  Serotyping is performed at the Statens Serum Institute in Denmark by the Quellung method. 





  Population-based surveillance in the state of Alaska o Since 1980 for invasive H. influenzae. o Since 1986 for invasive S. pneumoniae. o Since 1999 for invasive diseases caused by N. meningitidis, GAS, and GBS. o Coordinated by the Arctic Investigations Program (AIP), National Center for Infectious Disease, Centers 
for Disease Control and Prevention, in Anchorage, Alaska. 
  23 laboratories provide diagnostic services to residents of Alaska and submit to AIP isolates of S. 
pneumoniae, H. influenzae, N. meningitidis, GAS, and GBS cultured in blood, cerebrospinal fluid, or from 
other sterile sites. o S. pneumoniae and H. influenzae isolates are serotyped by the Quellung method using Statens Serum 
Institute antisera. o Serogroup testing of N. meningitidis was done using real-time PCR to detect the ctaA gene (capsule 
transport), as well as the genes required for serogroup-specfic capsule biosynthesis.   
  Antimicrobial susceptibility testing of S. pneumoniae isolates is performed at AIP by micro-broth dilution 
(according to NCCLS recommendations). 
  Clinical and demographic information on each case-patient is recorded by AIP research nurses onto the 
same collection form (BDSF) used in Greenland, Iceland, and Northern Canada. 




Streptococcus pneumoniae:  Currently 37 clinical laboratories in the U.S. Arctic and N. Canada forward isolates 
from patients with invasive pneumococcal disease to reference laboratories in Alaska and Canada respectively.  
To ensure inter-laboratory comparability of S. pneumoniae serotyping and antimicrobial susceptibility testing 
between two reference laboratories in Canada (Alberta and Quebec) and one in the U.S. (Alaska), the ICS S. 
pneumoniae inter-laboratory quality control (QC) program was established in 1999.  Statens Serum Institute, 
Copenhagen, Denmark, joined the program in 2004. 
 
Each reference laboratory is responsible for exporting one QC panel of seven S. pneumoniae isolates each year 
to each of the other laboratories using a transportation medium of their choice for a total of 28 Strep 
pneumoniae isolates in 2004.  Serotyping was performed by Quellung reaction.  Minimum inhibitory 
concentration (MIC) is determined for each QC isolate and for ATCC strain 49619 for those antibiotics which 
are routinely tested in each laboratory.  MIC results for each laboratory are expected to be within one log2 dilution of each other regardless of testing method.  Discrepancies of results are documented and examined to 
determine causes and solutions. 
 
Neisseria meningitidis/Haemophilus influenzae:  An interlaboratory quality control program for Neisseria 
meningitidis and Haemophilus influenzae was established in 2005.  Participating laboratories include the 
National Microbiology Laboratory, Winnipeg, Manitoba, Canada; Arctic Investigations Program, Anchorage, 
Alaska, USA; Laboratoire Santé Publique du Québec, Sainte-Anne-de-Bellevue, Québec, Canada; National 
Centre for Streptococcus, Edmonton, Alberta, Canada; and Statens Serum Institut, Copenhagen, Denmark.  
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A total of 1,987 cases of invasive disease caused by S. pneumoniae were reported to ICS during 2005 by 
Finland, Greenland, Iceland, N. Canada, N. Sweden, Norway, and the U.S. Arctic.  The highest rates of disease 
(29.8 per 100,000) occurred in Greenland and the lowest in N. Sweden (9.1 per 100,000) with an overall rate for 
the ICS circumpolar region of 17.6 per 100,000; 52% of all cases occurred in males.  The median age of cases 
overall was 58 years with the lowest median age in N. Canada (6 years) and the highest in Norway (62 years).  
Case fatality ratios ranged from 5% in N. Canada to 25% in Greenland; the overall case fatality ratio was 7%. 
 










Finland 5,255,580 735 14 401 (55) 55 (0-95) ‡ 
Greenland 56,969 17 29.8 8 (47) 48 (24-91) 4 (25)a 
Iceland 295,864 38 12.8 24 (63) 53 (0.4-95) ‡ 
N. Canada 132,956 23 17.3 15 (65) 6 (0-77) 1 (5)a 
N. Sweden 251,740 23 9.1 9 (39) 61 (1.7-89) ‡ 
Norway 4,606,363 1,029 22.3 503 (49) 62 (0-97) 70 (14)a 
U.S. Arctic 663,661 122 18.4 69 (57) 42 (0.2-90) 12 (10)a 
Total 11,263,133 1,987 17.6 1,029 (52) 58 (0-97) 87 (13) 
*Number of cases per 100,000 per year 
†Case fatality ratio 
‡Case outcomes not reported from Finland, Iceland, N. Sweden 
aCase outcomes unknown in 1 case from Greenland, 2 cases from N. Canada, 535 cases from Norway, 1 case from U.S. Arctic  
Streptococcus pneumoniae by Age Category, ICS 2005 Data 
Age  Finland Greenland Iceland N. Canada N. Sweden Norway U.S. Arctic 
<2 yrs 
Pop 115,509 1,670 8,499 4,849 4,789 114,499 21,121 
N (%) 73 (10) 0 (0) 8 (21) 8 (35) 1 (4) 85 (8) 18 (15) 
Rate* 63.2 0 94.1 165 20.9 74.2 85.2 
2-19 
yrs 
Pop 1,112,337 17,133 78,668 44,845 53,227 1,083,862 194,002 
N (%) 61 (8) 0 (0) 4 (10) 4 (17) 0 (0) 59 (6) 16 (13) 
Rate* 5.5 0 5.1 8.9 0 5.4 8.2 
20-64 
yrs 
Pop 3,186,569 35,023 173,984 77,823 145,638 2,730,282 405,162 
N (%) 371 (51) 14 (82) 11 (30) 7 (31) 14 (61) 408 (40) 67 (55) 
Rate* 11.6 40 6.3 9 9.6 14.9 16.5 
65+ 
yrs 
Pop 841,165 3,143 34,713 5,439 48,077 677,720 43,376 
N (%) 230 (31) 3 (18) 15 (39) 4 (17) 8 (35) 477 (46) 21 (17) 
Rate* 27.3 95.5 43.2 73.5 16.6 70.4 48.4 
All 
ages 
Pop 5,255,580 56,969 295,864 132,956 251,740 4,606,363 663,661 
N 735 17 38 23 23 1,029 122 
Rate* 14 29.8 12.8 17.3 9.1 22.3 18.4 
*Number of cases per 100,000 per year  
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When stratified by age, the highest rates of disease in all countries occurred in those cases less than two years of 
age and in cases 65+ years of age, with the exception of Greenland, where no cases were reported in individuals 




S. pneumoniae was diagnosed throughout the year in 2005 in each country.  For all countries, higher proportions 
of disease were seen in the first and second quarters of the year with declines during the third quarter.  In all 




Race and ethnicity data were collected in N. Canada and the U.S. Arctic.  Rates of invasive pneumococcal 
disease were higher in Aboriginal and Native populations than in non-Aboriginal and non-Native populations 
with the exception of non-Aboriginals less than 2 years old in N. Canada.  The highest rates of disease occurred 
in children less than 2 years of age and adults 65+ in both countries.   
 
Streptococcus pneumoniae by Race and Age Categories, ICS 2005 Data 
Age 
(yrs) 
 N. Canada* U.S. Arctic 
Aboriginal Non-Aboriginal Native Non-Native 
<2 Population 3,597 1,252 6,156 14,965 Cases (rate‡) 3 (83.4) 3 (239.6) 14 (227.4) 4 (26.7) 
2-19 Population 31,840 13,005 48,568 145,434 Cases (rate‡) 4 (12.6) 0 (0) 7 (14.4) 9 (6.2) 
20-64 Population 37,377 40,446 67,520 337,642 Cases (rate‡) 5 (13.4) 1 (2.5) 35 (51.8) 32 (9.5) 
65+ Population 3,036 2,403 7,350 36,026 Cases (rate‡) 3 (98.8) 1 (41.6) 5 (68) 16 (44.4) 
All 
Ages 
Population 75,850 57,106 129,594 534,067 
Cases (rate‡) 15 (19.8) 5 (8.8) 61 (47.1) 61 (11.4) 
*Race unknown in 2 cases < 2 years, 1 case 20-64 years 
‡Number of cases per 100,000 per year  
Clinical Presentation 
 
The most common clinical presentations associated with S. pneumoniae were pneumonia, bacteremia, and 
meningitis.  Clinical diagnoses other than bacteremia and meningitis are not reported in the Finland and N. 
Sweden S. pneumoniae data.  In Greenland, N. Canada, Norway, and the U.S. Arctic the clinical presentation 
reported most often was pneumonia (59%, 48%, 59% and 57%, respectively); in Finland, Iceland and N. 



















Pneumonia* 0 (0) 10 (59) 0 (0) 11 (48) 0 (0) 604 (59) 70 (57) 
Bacteremia 708 (96) 4 (24) 37 (97) 8 (35) 22 (96) 310 (30) 31 (25) 
Meningitis 27 (4) 3 (17) 1 (3) 3 (13) 1 (4) 72 (7) 6 (5) 
Empyema 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 12 (10) 
Septic arthritis 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (<1) 2 (2) 
Pericarditis 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (1) 
Other 0 (0) 0 (0) 0 (0) 1 (4) 0 (0) 42 (4) 0 (0) 
Total Cases 735 17 38 23 23 1,029 122 
*with bacteremia  
Risk Factors 
 
N. Canada and the U.S. Arctic report medical conditions or risk factors associated with S. pneumoniae.  In 
adults 18 years and older, cigarette smoking and alcohol abuse were the most common associated conditions 
occurring in 18 to 46% of patients. 
 
Streptococcus pneumoniae Risk Factor/Medical Conditions in Adults*, ICS 2005 Data 




Cigarette Smoking 2 (18) 41 (46) 
Alcohol Abuse 4 (36) 36 (40) 
Chronic Lung Disease and/or Asthma 0 (0) 18 (20) 
Immunosuppressive Therapy 1 (9) 5 (6) 
Diabetes 0 (0) 13 (15) 
Injection Drug Use 0 (0) 3 (3) 
Asplenia 0 (0) 0 (0) 
Total Adult* Cases 11 89 
*≥ 18 years  
Vaccination Policy 
 
In Finland, Iceland, N. Canada, Norway, and the U.S. Arctic, 23-valent pneumococcal polysaccharide vaccine 
(PS23) is recommended for persons 55 years and older (U.S. Arctic), over 60 years (Iceland) or over 65 years of 
age (Finland, N. Canada, Norway), and to persons greater than two years of age (Finland, Iceland, Norway, U.S. 
Arctic) or greater than five years of age (N. Canada) with specific medical problems.  The vaccine is only 
recommended for certain risk groups in N. Sweden.  The pneumococcal 7-valent conjugate vaccine (PCV7) was 
introduced into the infant immunization schedule in the U.S. Arctic in January, 2001, and has been used in some 




Forty and 94 percent of S. pneumoniae cases in children less than 2 years of age with known vaccination status 
were vaccinated with PCV7 in N. Canada and the U.S. Arctic, respectively.  Only 2% of cases eligible for PS23 
in Norway were vaccinated indicating much less frequent use of this vaccine than in N. Canada and the U.S. 









Total cases eligible for PCV7 vaccine* 8 a 18 
Vaccine status known in cases eligible for PCV7 5 a 18 
Cases eligible for PCV7 vaccinated (%)† 2 (40) a 17 (94) 
Total cases eligible for PS23 vaccine‡ 4 477 38 
Vaccine status known in cases eligible for PS23 4 187 17 
Cases eligible for PS23 vaccinated (%)† 2 (50) 4 (2) 12 (71) 
*Children less than 2 years of age 
†Percent of vaccine status known cases 
‡Adults 55 years and older in the U.S. Arctic, 65 years and older in N. Canada and Norway 
aPCV7 is not used routinely in Norway  
Serotypes 
 
The most prevalent S. pneumoniae serotypes reported by ICS countries in 2005 were 4 and 14; both are 
included in the 23-valent pneumococcal polysaccharide vaccine and the 7-valent conjugate vaccine.  In the 
following table, yellow highlights the most common serotypes in each country. 
 














1 3 (<1) 2 (13) 3 (8) 16 (6) 3 (14) 3 (3) 
3 47 (6) 2 (13) 3 (8) 8 (2) 3 (14) 10 (9) 
4 72 (10) 3 (20) 4 (11) 53 (18) 0 (0) 3 (3) 
6 0 (0) 0 (0) 0 (0) 25 (9) 0 (0) 0 (0) 
6A 24 (3) 0 (0) 2 (5) 0 (0) 1 (5) 2 (2) 
6B 55 (7) 1 (7) 1 (3) 0 (0) 2 (9) 1 (1) 
7 0 (0) 0 (0) 0 (0) 21 (7) 0 (0) 0 (0) 
7C 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (1) 
7F 48 (7) 0 (0) 2 (5) 0 (0) 1 (5) 16 (14) 
8 10 (1) 0 (0) 0 (0) 4 (1) 1 (5) 11 (10) 
9 0 (0) 0 (0) 0 (0) 32 (11) 0 (0) 0 (0) 
9A 1 (<1) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 
9N 27 (4) 0 (0) 0 (0) 0 (0) 0 (0) 1 (1) 
9V 60 (8) 0 (0) 1 (3) 0 (0) 0 (0) 2 (2) 
10 7 (1) 0 (0) 0 (0) 2 (<1) 0 (0) 0 (0) 
10A 0 (0) 0 (0) 0 (0) 0 (0) 1 (5) 5 (4) 
11 0 (0) 0 (0) 0 (0) 2 (<1) 0 (0) 0 (0) 
11A 13 (2) 0 (0) 0 (0) 0 (0) 0 (0) 3 (3) 
12 0 (0) 0 (0) 0 (0) 1 (<1) 0 (0) 0 (0) 
12F 22 (3) 1 (7) 0 (0) 0 (0) 0 (0) 10 (9) 
14 109 (15) 0 (0) 7 (19) 53 (18) 0 (0) 2 (2) 
15 0 (0) 0 (0) 0 (0) 2 (<1) 0 (0) 0 (0) 
15A 1 (<1) 0 (0) 0 (0) 0 (0) 1 (5) 2 (2) 
15B 4 (<1) 0 (0) 0 (0) 0 (0) 0 (0) 2 (2) 
15C 3 (<1) 0 (0) 0 (0) 0 (0) 0 (0) 2 (2) 
















16F 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (1) 
17 2 (<1) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 
17F 0 (0) 0 (0) 0 (0) 0 (0) 1 (5) 2 (2) 
18 0 (0) 0 (0) 0 (0) 5 (2) 0 (0) 0 (0) 
18B 1 (<1) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 
18C 39 (5) 2 (13) 1 (3) 0 (0) 2 (9) 2 (2) 
19 0 (0) 0 (0) 0 (0) 17 (6) 0 (0) 0 (0) 
19A 31 (4) 1 (7) 1 (3) 0 (0) 1 (5) 17 (15) 
19B 1 (<1) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 
19C 0 (0) 0 (0) 1 (3) 0 (0) 0 (0) 0 (0) 
19F 36 (5) 0 (0) 3 (8) 0 (0) 0 (0) 1 (1) 
20 3 (<1) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 
22 0 (0) 0 (0) 1 (3) 12 (4) 0 (0) 0 (0) 
22F 21 (3) 3 (20) 0 (0) 0 (0) 1 (5) 6 (5) 
23 0 (0) 0 (0) 0 (0) 22 (8) 0 (0) 0 (0) 
23A 4 (<1) 0 (0) 0 (0) 0 (0) 0 (0) 1 (1) 
23B 0 (0) 0 (0) 0 (0) 0 (0) 1 (5) 0 (0) 
23F 0 (0) 0 (0) 6 (16) 0 (0) 2 (9) 1 (1) 
28 0 (0) 0 (0) 0 (0) 1 (<1) 0 (0) 0 (0) 
29 0 (0) 0 (0) 0 (0) 1 (<1) 0 (0) 0 (0) 
31 0 (0) 0 (0) 0 (0) 1 (<1) 0 (0) 0 (0) 
33 2 (<1) 0 (0) 0 (0) 8 (3) 0 (0) 0 (0) 
33F 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 2 (2) 
34 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 2 (2) 
35 0 (0) 0 (0) 0 (0) 2 (<1) 0 (0) 0 (0) 
35B 5 (<1) 0 (0) 0 (0) 0 (0) 1 (5) 1 (1) 
35F 6 (1) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 
38 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (1) 
 
Vaccine-Preventable Cases and Deaths 
 For the countries reporting serotype data, more than 80% of S. pneumoniae cases in persons ≥ 2 years of age 
were preventable with use of the 23-valent polysaccharide vaccine.  Use of the 7-valent conjugate vaccine 
would have potentially prevented 88% of S. pneumoniae cases in children < 2 years of age in Iceland and 75% 
of cases < 2 years of age in Finland.  Eleven percent of remaining disease in U.S. Arctic children less than 2 
was vaccine preventable reflecting widespread introduction of this vaccine four years earlier and near 
elimination of vaccine preventable disease in this population.  The proportion of deaths among S. pneumoniae  




















Cases ≥ 2 years old with serotype in the 












Cases < 2 years old with serotype in the 










Deaths (all ages) for which the serotype 











*Number of isolates serotyped by country by age group 
†Serotype data not matched with case data in Finland; outcome data not reported in Iceland 
‡Percentage of total death  
Outcome 
 
A total of 87 deaths associated with S. pneumoniae were reported to ICS in 2005.  Overall, the highest case 
fatality ratio (CFR) occurred in persons 65+ years of age (24%).  Finland, Iceland and N. Sweden did not report 
outcome data. 
 
Streptococcus pneumoniae Age-Specific Case-Fatality Ratios (CFR), ICS 2005 Data 
  <2 years 2-19 years 20-64 years 65+ years All Ages 
Greenland Deaths/Cases* (CFR) 0/0 (0) 0/0 (0) 2/13 (15)† 2/3 (67) 4/16 (25)† 
N. Canada Deaths/Cases* (CFR) 0/7 (0)† 0/4 (0) 1/7 (14) 0/3 (0)† 1/21 (5)† 





U.S. Arctic Deaths/Cases* (CFR) 0/18 (0) 0/16 (0) 7/66 (11)† 5/21 (24) 
12/121 
(10)† 







*Cases with known outcome.   
†Outcome unknown in (1) N. Canada and (30) Norway cases < 2 years, (27) Norway cases 2-19 years, 1 Greenland (220) Norway and 
(1) U.S. Arctic cases 20-64 years, (1) N. Canada and (258) Norway cases 65+ years  
Antimicrobial Susceptibility 
 
In 2005, antimicrobial susceptibility results were reported to ICS from Finland, Greenland, Iceland, N. Canada, 
N. Sweden and the U.S. Arctic.  Of those isolates tested from the U.S. Arctic, three (3%) were fully resistant to 
penicillin (serotypes 9V, 19A, 23F), and 12% had intermediate resistance (serotypes 6A (7%), 9V (7%), 19A 
(71%), 23A (7%) and 35B (7%)).  Finland submitted results from 735 isolates; 2% were fully resistant to 
penicillin and 5% had intermediate resistance.  The Finnish serotype data is not linked to the antimicrobial 
susceptibility data, so no comparisons can be made.  In Iceland, 8% of isolates tested had intermediate 
resistance to penicillin and consisted of serotypes 14 (33%), 19C (33%) and 19F (33%).  In N. Canada, one 
isolate had intermediate resistance (serotype 19A) and one was fully resistant (serotype 6A).  N. Sweden did not 
report serotype data, however, 21 isolates were tested and all were sensitive to penicillin. 
 
Streptococcus pneumoniae Penicillin Susceptibility Results, ICS 2005 Data 
 
14 
 # Tested I* (%) I* Serotypes R* (%) R* Serotypes 
Finland 735 37 (5) † 12 (2) † 
Greenland 8 0 (0)  0 (0)  
Iceland 36 3 (8) 14 (1), 19C (1), 19F (1) 0 (0)  
N. Canada 22 1 (5) 19A 1 (5) 6A  
N. Sweden 21 0 (0)  0 (0)  
U.S. Arctic 113 14 (12) 6A (1), 9V (1), 19A (10), 23A (1), 35B (1) 3 (3) 
9V (1), 19A (1), 
23F (1) 
*I=Intermediate resistance, R=Fully resistant 
†Finnish serotype data is not linked to antimicrobial susceptibility data  
Full resistance to trimethoprimsulfamethoxizole (TMP-Sulfa) was found in 19% of tested isolates from Iceland 
and 10% from the U.S. Arctic.  Isolates from Iceland that were fully resistant to TMP-Sulfa were serotypes 6A 
(29%), 23F (29%), and one each of serotypes 14, 19C and 19F.  The isolates that were fully resistant in the U.S. 
Arctic were serotypes 19A (45%), 9V (18%) and one each 6B, 11A, 23F and 33F.  Intermediate resistance to 
TMP-Sulfa was found in 15% of tested isolates from Iceland, 10% from the U.S. Arctic, and 3% from N. 
Canada.   
 
Streptococcus pneumoniae TMP-Sulfa Susceptibility Results, ICS 2005 Data 
 # Tested I* (%) I* Serotypes R* (%) R* Serotypes 
Iceland 36 1 (3) 23F 7 (19) 6A (2), 14 (1), 19C (1), 19F (1), 23F (2) 
N. Canada 20 3 (15) 6A (1), 6B (1), 23B (1) 
0 (0)  
U.S. Arctic 113 11 (10) 12F (3), 18C (1), 19A (6), 33F (1) 11 (10) 
6B (1), 9V (2), 11A (1), 
19A (5), 23F (1), 33F (1) 
*I=Intermediate resistance, R=Fully resistant  
In Iceland, 14% of tested isolates were fully resistant to erythromycin, 10% from N. Canada, and 9% from the 
U.S. Arctic.  In Iceland, the isolates that were fully resistant to erythromycin were serotypes 14 (60%), 19C 
(20%) and 19F (20%).  In N. Canada, resistant isolates were one each 6A and 6B.  In the U.S. Arctic, isolates 
that were fully resistant were serotypes 19A (30%), 9V (20%) and one each 6A, 6B, 14, 23F and 35B. 
 
Streptococcus pneumoniae Erythromycin Susceptibility Results, ICS 2005 Data 
 # Tested I* (%) I* Serotypes R* (%) R* Serotypes 
Iceland 36 0 (0)  5 (14) 14 (3), 19C (1), 19F (1) 
N. Canada 21 0 (0)  2 (10) 6A (1), 6B (1) 
N. Sweden 23 0 (0)  0 (0)  
U.S. Arctic 113 0 (0)  10 (9) 6A (1), 6B (1), 9V (2), 14 (1), 19A (3), 23F (1), 35B (1) 
*I=Intermediate resistance, R=Fully resistant  
Antimicrobial testing was also done for ceftriaxone, ofloxacin/levofloxacin, chloramphenicol, vancomycin, 
clindamycin, and rifampin.  One of 112 (1%) isolates tested in the U.S. Arctic was fully resistant to 
chloramphenicol (serotype 23F) and one (1%) was fully resistant to rifampin (serotype 14).  In N. Canada, two 
isolates of 20 tested (10%) were fully resistant to clindamycin (serotypes 6A, 6B).  All isolates tested in N. 






In 2005, two QC panels of seven S. pneumoniae isolates plus a control strain each were shipped and tested.  
MIC data was analyzed in two ways.  The first comparison is based on MIC data provided by the distributing 
laboratory and is the method used historically in the QC program.  The new methodology provides an analysis 
of MIC data for all the participating laboratories by using the modal MIC for each antibiotic-organism 
combination as the value to which the other data are compared.  The modal MIC is the MIC most frequently 
reported.  When two MIC values were reported with equal frequency, both were accepted as a modal value.  
Antibiotic-organism combinations for which there was no consensus on a modal MIC were excluded from the 
analysis.  The rationale for initiating the second analysis recognizes that there is an allowable variation of one 
log2 dilution inherent for any MIC testing system.  This means that there is no one absolutely correct MIC value to which all others can be compared.  The modal MIC may be a better representation of this ‘true’ value than 
any one laboratory can provide.  For Panel 2005-A, overall serotyping performance ranged between 80%-90%.  
The modal MIC comparison resulted in an overall correlation of 96.6% with individual participant correlation 
ranging from 85%-100%.  For Panel 2005-B, overall serotyping correlation was 100%.  The overall modal MIC 




Streptococcus pneumoniae remains a major cause of invasive bacterial disease in circumpolar regions.  Disease 
rates are highest in indigenous populations.  The impact of the conjugate vaccine is clear in the U.S. Arctic.  
Surveillance for evidence of impact in other circumpolar countries will be important to confirm effectiveness 







Greenland, N. Canada, N. Sweden and the U.S. Arctic reported the occurrence of H. influenzae in each country 
during 2005.  Greenland reported no cases and therefore will not be included in the results.  A total of 22 cases 
of invasive disease caused by H. influenzae were reported to ICS during 2005 by N. Canada, N. Sweden and the 
U.S. Arctic.  The rate of disease was higher in N. Canada (8.3 per 100,000) than it was in the U.S. Arctic (1.4 
per 100,000) or N. Sweden (0.8 per 100,000).  Median age of cases was higher in N. Sweden (80.4 years) than 
in N. Canada and the U.S. Arctic (1 year and 3.6 years, respectively), however, only 2 cases were reported in N. 
Sweden.   
 










N. Canada 132,956 11 8.3 7 (64) 1 (0.2-66.1) 1 (11)† 
N. Sweden 251,740 2 0.8 0 (0) 80.4 (75-85) † 
U.S. Arctic 663,661 9 1.4 7 (78) 3.6 (0.5-73) 1 (11) 
Total 1,048,357 22 2.1 14 (64) 1.4 (0.2-85) 2 (11) 
*Number of cases per 100,000 per year 
†Case fatality ratio 
‡ Case outcome unknown in (2) N. Canada cases; N. Sweden did not report case outcomes  
When stratified by age, the highest rates of disease for both N. Canada and the U.S. Arctic were in the <2 years 
and 65+ years age categories; no disease was reported in the <2 years age category in N. Sweden.   
 
Haemophilus influenzae by Age Category, ICS 2005 Data 
Age  N. Canada N. Sweden U.S. Arctic 
<2 yrs 
Population 4,849 4,789 21,121 
Cases (%) 10 (91) 0 (0) 3 (33) 
Rate* 206.2 0 14.2 
2-19 yrs 
Population 44,845 53,227 194,002 
Cases (%) 0 (0) 0 (0) 2 (22) 
Rate* 0 0 1 
20-64 yrs 
Population 77,823 145,638 405,162 
Cases (%) 0 (0) 0 (0) 3 (33) 
Rate* 0 0 0.7 
65+ yrs 
Population 5,439 48,077 43,376 
Cases (%) 1 (9) 2 (100) 1 (11) 
Rate* 18.4 4.2 2.3 
All ages  
Population 132,956 251,740 663,661 
Cases 11 2 9 
Rate* 8.3 0.8 1.4 







Race and ethnicity data was unknown in 2 of the 11 H. influenzae cases from N. Canada.  Rates of disease were 
highest (194.6 per 100,000) in N. Canada Aboriginal cases less than two years of age.  In the U.S. Arctic, rates 
of disease were higher in Native populations than in non-Native populations in children less than 2 years old 
and persons 2-19 years old.  There were no cases reported in Native people older than 19 years. 
 
Haemophilus influenzae by Race and Age Categories, ICS 2005 Data 
Age 
(yrs) 
 N. Canada* U.S. Arctic 
Aboriginal Non-Aboriginal Native Non-Native 
<2 Population 3,597 1,252 6,156 14,965 Cases (rate†) 7 (194.6) 1 (79.9) 2 (32.5) 1 (6.7) 
2-19 Population 31,840 13,005 48,568 145,434 Cases (rate†) 0 (0) 0 (0) 1 (2.1) 1 (0.7) 
20-64 Population 37,377 40,446 67,520 337,642 Cases (rate†) 0 (0) 0 (0) 0 (0) 3 (0.9) 
65+ Population 3,036 2,403 7,350 36,026 Cases (rate†) 0 (0) 1 (41.6) 0 (0) 1 (2.8) 
All 
Ages 
Population 75,850 57,106 129,594 534,067 
Cases (rate†) 7 (9.2) 2 (3.5) 3 (2.3) 6 (1.1) 
*Race unknown in 2 cases <2 years 
†Number of cases per 100,000 per year  
Clinical Presentation 
 
In N. Canada and N. Sweden, the most common clinical presentation associated with H. influenzae was 
bacteremia (55% and 100% of reported cases, respectively).  In the U.S. Arctic, the most common clinical 
presentation was pneumonia (67%) followed by meningitis (33%). 
 
Clinical Presentation of Reported Haemophilus influenzae Cases, ICS 2005 Data 






Pneumonia* 3 (27) 0 (0) 6 (67) 
Bacteremia 6 (55) 2 (100) 0 (0) 
Meningitis 1 (9) 0 (0) 3 (33) 
Septic arthritis 1 (9) 0 (0) 0 (0) 
Total 11 2 9 
*with bacteremia  
Risk Factors 
 
Fifty percent of adult (≥ 18 years) cases of H. influenzae reported in the U.S. Arctic indicated smoking or 
chronic lung disease as an associated risk factor; 25% indicated alcohol abuse, immune suppressive treatment or 
diabetes as an associated risk factor.  No risk factors were reported in the one Canadian adult case of H. 






The H. influenzae type b (Hib) conjugate vaccine is required as part of routine childhood vaccination in N. 
Canada and the U.S. Arctic.  Two cases of Hib were reported in N. Canada and 3 cases in the U.S. Arctic in 
children less than five years.  One Hib case in N. Canada had received one dose of Hib vaccine; vaccine history 
was unknown in the second case.  In the U.S. Arctic, one Hib case was unvaccinated and two others had 
received three doses of Hib vaccine. 
 





Total cases* eligible for Hib vaccine† 10 5 
Vaccine status known in cases* eligible for Hib vaccine 9 5 
Cases* eligible for Hib vaccine vaccinated (%)‡ 7 (78%) 4 (80%) 
*All serotypes 
†Children less than 5 years of age 
‡Percent of vaccine status known cases  
Serotypes 
 
Haemophilus influenzae Serotypes by Country, ICS 2005 Data 




a 5 (46) 1 (11) 
b 2 (18) 4 (44) 
f 0 (0) 2 (22) 
Non-typeable 4 (36) 2 (22) 
Total 11 9 
 
The most common H. influenzae serotype in N. Canada was type a (46% of cases); in the U.S. Arctic it was 
type b (44% of cases). Non-typeable cases also made up a large proportion of cases in each country; 36% in N. 




Two deaths were associated with H. influenzae cases reported to ICS in 2005; one from the U.S. Arctic and one 
from N. Canada.  N. Sweden did not provide outcome data.  Both deaths were in children less than one year old 
who had received Hib vaccine and the primary clinical presentation was pneumonia.  The N. Canada case was a 




Widespread use of Hib conjugate vaccines has led to the virtual disappearance of Hib disease in these 







Greenland, N. Canada, Norway and the U.S. Arctic reported the occurrence of N. meningitidis during 2005.  A 
total of 42 cases of invasive disease caused by N. meningitidis were reported to ICS.  Greenland had the highest 
disease rate (1.8 per 100,000).  Six deaths associated with N. meningitidis were reported. 
 










Greenland 56,969 1 1.8 1 (100) 1 case – 40.5 0 (0) 
N. Canada 132,956 1 0.8 1 (100) 1 case – 51.7 0 (0) 
Norway 4,606,363 37 0.8 18 (49) 23 (0-98) 5 (14) 
U.S. Arctic 663,661 3 0.5 1 (33) 5.2 (3.1-39.8) 1 (33) 
Total 5,459,949 42 0.8 21 (50) 26 (0-98) 6 (14) 
*Number of cases per 100,000 per year 
†Case fatality ratio  
When stratified by age, the highest rates of disease in each country occurred in different age categories.  In 
Greenland and N. Canada, one case was reported in each country and both occurred in 20-64 year old age 
category.  Cases occurred in all age categories in Norway; the highest rate was in the less than 2 years category 
(2.6/100,000).  In the U.S. Arctic, the highest rates of disease occurred in the 2-19 year old age category 
(1/100,000). 
 
  Neisseria meningitidis by Age Category, ICS 2005 Data 
Age  Greenland N. Canada Norway U.S. Arctic 
<2 
yrs 
Pop 1,670 4,849 114,499 21,121 
N (%) 0 (0) 0 (0) 3 (8) 0 (0) 
Rate* 0 0 2.6 0 
2-19 
yrs 
Pop 17,133 44,845 1,083,862 194,002 
N (%) 0 (0) 0 (0) 13 (35) 2 (67) 
Rate* 0 0 1.2 1 
20-64 
yrs 
Pop 35,023 77,823 2,730,282 405,162 
N (%) 1 (100) 1 (100) 13 (35) 1 (33) 
Rate* 2.9 1.3 0.5 0.2 
65+ 
yrs 
Pop 3,143 5,439 677,720 43,376 
N (%) 0 (0) 0 (0) 8 (22) 0 (0) 
Rate* 0 0 1.2 0 
All 
ages 
Pop 56,969 132,956 4,606,363 663,661 
N 1 1 37 3 
Rate* 1.8 0.8 0.8 0.5 





In the U.S. Arctic, all three cases of N. meningitidis occurred in AK Native people (rate 2.3/100,000).  In N. 




The most common clinical presentation in all countries reporting invasive N. meningitis in 2005 was meningitis 
ranging from 62% to 100% of cases.   
 









Pneumonia* 0 (0) 0 (0) 4 (11) 0 (0) 
Bacteremia 0 (0) 0 (0) 10 (27) 0 (0) 
Meningitis 1 (100) 1 (100) 23 (62) 2 (67) 
Septic arthritis 0 (0) 0 (0) 0 (0) 1 (33) 
Total 1 1 37 3 
*with bacteremia  
Risk Factors 
 
Risk factor data was reported by N. Canada and the U.S. Arctic; no adult cases (n=2) in either country indicated 




All cases of invasive N. meningitidis reported to ICS in 2005 included serogroup data.  With the exception of N. 
Canada, the most common serogroup was B which occurred in 68% to 100% of cases.  In N. Canada, the one 
reported case was a serogroup Y. 
 









B 1 (100) 0 (0) 25 (68) 3 (100) 
C 0 (0) 0 (0) 5 (13) 0 (0) 
W 0 (0) 0 (0) 1 (3) 0 (0) 
W135 0 (0) 0 (0) 3 (8) 0 (0) 
Y 0 (0) 1 (100) 3 (8) 0 (0) 




Neisseria meningitidis is a relatively uncommon cause of invasive bacterial disease in the circumpolar area 








Greenland, N. Canada, N. Sweden and the U.S. Arctic each reported the occurrence of GAS during 2005.  A 
total of 55 cases of invasive disease caused by GAS were reported to ICS.  The rate of disease was highest in N. 
Canada (10.5 per 100,000) compared to the lowest in N. Sweden (1.6 per 100,000).  Three deaths were 
associated with GAS, one in N. Canada and two in the U.S. Arctic. 
 
Group A Streptococcus Case Demographics, ICS 2005 Data 







Greenland 56,969 1 1.8 0 (0) 1 case – 53.3 0 (0) 
N. Canada 132,956 14 10.5 8 (57) 46.2 (0.3-88.9) 1 (7) 
N. Sweden 251,740 4 1.6 3 (75) 70.7 (64.8-84.6) ‡ 
U.S. Arctic 663,661 36 5.4 14 (39) 42.6 (1.2-76.8) 2 (6) 
Total 1,105,326 55 5 25 (45) 46.6 (0.3-88.9) 3 (6) 
*Number of cases per 100,000 per year 
†Case fatality ratio 
‡Outcomes not reported from N. Sweden  
When stratified by age, the highest rates of disease occurred in children <2 years and in individuals 65+ years of 
age in N. Canada (62 per 100,000 and 55 per 100,000, respectively).   
 
Group A Streptococcus by Age Category, ICS 2005 Data 
Age  Greenland N. Canada N. Sweden U.S. Arctic 
<2 yrs 
Population 1,670 4,849 4,789 21,121 
Cases (%) 0 (0) 3 (22) 0 (0) 2 (6) 
Rate* 0 61.9 0 9.5 
2-19 yrs 
Population 17,133 44,845 53,227 194,002 
Cases (%) 0 (0) 0 (0) 0 (0) 4 (11) 
Rate* 0 0 0 2.1 
20-64 yrs 
Population 35,023 77,823 145,638 405,162 
Cases (%) 1 (100) 8 (57) 1 (25) 27 (75) 
Rate* 2.9 10.3 0.7 6.7 
65+ yrs 
Population 3,143 5,439 48,077 43,376 
Cases (%) 0 (0) 3 (22) 3 (75) 3 (8) 
Rate* 0 55.2 6.2 6.9 
All ages  
Population 56,969 132,956 251,740 663,661 
Total Cases 1 14 4 36 
Rate* 1.8 10.5 1.6 5.4 





Race and ethnicity data were collected by N. Canada and the U.S. Arctic.  Higher rates of disease occurred in all 
age categories in N. Canada Aboriginal people and U.S. Arctic Native people than in non-Aboriginal and non-
Native people. 
 
Group A Streptococcus by Race and Age Categories, ICS 2005 Data 
Age 
(yrs) 
 N. Canada* U.S. Arctic 
Aboriginal Non-Aboriginal Native Non-Native 
<2 Population 3,597 1,252 6,156 14,965 Cases (rate†) 3 (83.4) 0 (0) 1 (16.2) 1 (6.7) 
2-19 Population 31,840 13,005 48,568 145,434 Cases (rate†) 0 (0) 0 (0) 3 (6.2) 1 (0.7) 
20-64 Population 37,377 40,446 67,520 337,642 Cases (rate†) 7 (18.7) 1 (2.5) 12 (17.8) 15 (4.4) 
65+ Population 3,036 2,403 7,350 36,026 Cases (rate†) 2 (65.9) 1 (41.6) 3 (40.8) 0 (0) 
All 
Ages 
Population 75,850 57,106 129,594 534,067 
Cases (rate†) 12 (15.8) 2 (3.5) 19 (14.7) 17 (3.2) 
†Number of cases per 100,000 per year  
Clinical Presentation 
 
The most common clinical presentation for GAS cases in N. Sweden (100%) and the U.S. Arctic (28%) was 
bacteremia, in N. Canada it was cellulitis (29%), and the single case in Greenland presented with pericarditis.     
 









Bacteremia 0 (0) 3 (21) 4 (100) 10 (28) 
Pneumonia* 0 (0) 1 (7) 0 (0) 7 (25) 
Empyema 0 (0) 0 (0) 0 (0) 3 (8) 
Cellulitis* 0 (0) 4 (29) 0 (0) 5 (14) 
Necrotizing fasciitis 0 (0) 1 (7) 0 (0) 2 (6) 
Septic arthritis 0 (0) 2 (14) 0 (0) 4 (11) 
Osteomylitis 0 (0) 1 (7) 0 (0) 0 (0) 
Pericarditis 1 (100) 0 (0) 0 (0) 0 (0) 
Endometritis 0 (0) 0 (0) 0 (0) 1 (3) 
Peritonitis 0 (0) 0 (0) 0 (0) 1 (3) 
Amnionitis 0 (0) 1 (7) 0 (0) 1 (3) 
Other 0 (0) 1 (7) 0 (0) 3 (8) 
Total 1 14 4 36 





Cigarette smoking was associated with 37% and 18% of adult (≥18 years) GAS cases in the U.S. Arctic and, N. 
Canada respectively.  Thirty percent of U.S. Arctic and 27% of N. Canada case reviews indicated alcohol abuse 
as a risk factor.  In the U.S. Arctic, 17% of case reviews indicated diabetes or chronic lung disease and 3% 




Two deaths in cases with GAS were reported from the U.S. Arctic (CFR 6%); both occurred in the 20-64 years 
old age category.  One death was reported in N. Canada (CFR 7%); the death occurred in the 20-64 year old age 




These data suggest markedly higher rates in indigenous populations.  Increased awareness of risk may help 








Greenland, N. Canada, N. Sweden and the U.S. Arctic each reported the occurrence of GBS during 2005.  
Greenland reported no cases and therefore will not be included in the results.  A total of 36 cases of invasive 
disease caused by GBS were reported to ICS.  The rate of disease was highest in N. Sweden (4.4 per 100,000) 
compared to N. Canada (0.8 per 100,000).  Four deaths were reported in the U.S. Arctic associated with GBS in 
2005. 
 










N. Canada 132,956 1 0.8 1 (100) 1 case – 23.1 0 (0) 
N. Sweden 251,740 11 4.4 9 (82) 74.9 (51.4-90.7) ‡ 
U.S. Arctic 663,661 24 3.6 11 (46) 53.3 (0-89.7) 4 (17) 
Total 1,048,357 36 3.4 21 (58) 64.2 (0-90.7) 4 (16) 
*Number of cases per 100,000 per year 
†Case fatality ratio 
‡No outcomes reported from N. Sweden  
When stratified by age, the highest rates of disease occurred in cases less than two years of age in the U.S. 
Arctic (28 per 100,000) and in cases 65+ years in N. Sweden (19 per 100,000).   
 
Group B Streptococcus by Age Category, ICS 2005 Data 
Age  N. Canada N. Sweden U.S. Arctic 
<2 yrs 
Population 4,849 4,789 21,121 
Cases (%) 0 (0) 0 (0) 6 (25) 
Rate* 0 0 28.4 
2-19 yrs 
Population 44,845 53,227 194,002 
Cases (%) 0 (0) 0 (0) 0 (0) 
Rate* 0 0 0 
20-64 yrs 
Population 77,823 145,638 405,162 
Cases (%) 1 (100) 2 (18) 11 (46) 
Rate* 1.3 1.4 2.7 
65+ yrs 
Population 5,439 48,077 43,376 
Cases (%) 0 (0) 9 (82) 7 (29) 
Rate* 0 18.7 16.1 
All ages  
Population 132,956 251,740 663,661 
Total Cases 1 11 24 
Rate* 0.8 4.4 3.6 
*Number of cases per 100,000 per year  
Five of six cases that occurred in the U.S. Arctic in the less than 2 years age category were early onset (less than 






Race and ethnicity data were collected in N. Canada and the U.S. Arctic.  The overall rate of disease caused by 
GBS in AK Natives was almost three times that in non-Natives.  One case of GBS was reported in N. Canada 
Aboriginals. 
 
Group B Streptococcus by Race and Age Categories, ICS 2005 Data 
Age 
(yrs) 
 N. Canada U.S. Arctic 
Aboriginal Non-Aboriginal Native Non-Native 
<2 Population 3,597 1,252 6,156 14,965 Cases (rate*) 0 (0) 0 (0) 3 (48.7) 3 (20) 
2-19 Population 31,840 13,005 48,568 145,434 Cases (rate*) 0 (0) 0 (0) 0 (0) 0 (0) 
20-64 Population 37,377 40,446 67,520 337,642 Cases (rate*) 1 (2.7) 0 (0) 5 (7.4) 6 (1.8) 
65+ Population 3,036 2,403 7,350 36,026 Cases (rate*) 0 (0) 0 (0) 2 (27.2) 5 (13.9) 
All 
Ages 
Population 75,850 57,106 129,594 534,067 
Cases (rate*) 1 (1.3) 0 (0) 10 (7.7) 14 (2.6) 
*Number of cases per 100,000 per year  
Clinical Presentation 
 
In the U.S. Arctic, bacteremia (46%) was the most common clinical presentation reported for cases of GBS in 
2005 followed by cellulitis (17%), osteomyelitis (17%), pneumonia (13%), meningitis (4%) and amnionitis 
(4%).  The single case in N. Canada presented with bacteremia.  All cases in N. Sweden were reported as 
bacteremia which may reflect a difference in reporting practices. 
 
Clinical Presentation of Reported group B Streptococcus Cases, ICS 2005 Data 






Bacteremia 1 (100) 11 (100) 11 (46) 
Pneumonia* 0 (0) 0 (0) 3 (13) 
Meningitis 0 (0) 0 (0) 1 (4) 
Cellulitis* 0 (0) 0 (0) 4 (17) 
Osteomyelitis 0 (0) 0 (0) 4 (17) 
Amnionitis 0 (0) 0 (0) 1 (4) 
Total 1 11 24 
*with bacteremia  
Risk Factors 
 
Twenty-two percent of GBS adult (≥ 18 years) cases reviewed in the U.S. Arctic indicated diabetes or chronic 
lung disease as risk factors in 2005.  In 17% of cases, smoking or immune suppressive treatment were indicated 






Four deaths in cases with GBS were reported in the U.S. Arctic (CFR 17%); one death occurred in the less than 
2 years age category, two deaths occurred in the 20-65 years age category and one death occurred in the 65+ 




Guidelines for universal screening of pregnant women for GBS carriage were established in 2002 which have 





The ICS program continued to expand in 2005.  An Interlaboratory Quality Control program was established to 
provide external proficiency testing of N. meningitidis and H. influenzae.  Monitoring rates of disease and levels 
of antimicrobial resistance in S. pneumoniae, H. influenzae, N. meningitidis, GAS and GBS via use of the ICS 
system is important in providing data on groups at risk for disease, measurement of effectiveness of prevention 
measures, and emerging challenges in serotype distribution and antimicrobial resistance.  Efforts to 
expand ICS to include all circumpolar nations will continue. 
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National Public Health Institute (KTL) Laboratory, Oulu 
Laboratories Et.-Pohjanmaan sh-piiri, Seinäjoen sairaalan mikrobiol. lab. Etelä-Karjalan keskussairaalan kl.mikrobiologian laboratorio 
HY – Serobakteriologian laitos 
Jorvin sairaala, kliinisen mikrobiologian laboratorio 
KYS – Mikrobiologian laboratorio 
Kainuun keskussairaalan mikrobiologian laboratorio 
Kanta-Hämeen keskussairaalan mikrobiologian laboratorio 
Keski-Pohjanmaan keskussairaalan mikrobiologian laboratorio 
Keski-Suomen keskussairaalan mikrobiologian laboratorio 
Kymenlaakson keskussairaalan mikrobiologian laboratorio 
Lapin keskussairaalan mikrobiologian laboratorio 
Länsi-Pohjan keskussairaalan laboratorio 
Mikkelin keskussairaalan mikrobiologian laboratorio 
OYKS – Mikrobiologian laboratorio 
Oulun kiakonissalairoksen laboratorio 
Pohjois-Karjalan keskussairaalan mikrobiologian laboratorio 
Päijät-Hämeen keskussairaalan mikrobiologian laboratorio 
Rauman aluesairaalan laboratorio 
Satakunnan keskussairaalan mikrobiologian laboratorio 
Savonlinnan keskussairaalan laboratorio 
TAYS – Mikrobiologian laboratorio 
TYKS – Mikrobiologian laboratorio 





Statens Serum Institute, Copenhagen, Denmark 
Centralab at Queen Ingrid’s Hospital, Nuuk, Greenland 




















Department of Microbiology, Landspitali University Hospital, 
Reykjavik 
Laboratories Akranes Hospital Isafjordur District Hospital 
Stykkisholmur Local Health Center 
St. Joseph’s Hospital Hafnarfjorour 
Municipal Hospital of Vestmannaeyjar 
Akureyri 
Egilstadir Health Center 
Selfoss Health Center 
Sudurnes Health Center (Keflavik) 




for Disease Control 
Respiratory Division, Bureau of Infectious Diseases, Laboratory 
Centre for Disease Control, Ottawa 
Reference 
Laboratories 
National Centre for Streptococcus, Provincial Laboratory of Public 
Health, Edmonton, AB 
Laboratoire de Santé Publique du Québec, Montréal, QC 
National Centre for Meningococcus, Provincial Laboratory of Public 
Health, Winnipeg, MB 
Laboratories Whitehorse General Hospital, Whitehorse, YK Stanton Regional Health Board, Yellowknife, NT 
H.H. Williams Memorial Hospital, Hay River, NT 
Inuvik Regional Hospital, Inuvik, NT 
Baffin Regional Hospital, Iqaluit, NU 
Churchill Regional Health Authority, Churchill, MB 
Cadham Provincial Laboratory, Winnipeg, MB 
Ungava Tulattavik Health Centre, Kuujjuaq, QC 
Inulitsavik Hospital, Puvirnituq, QC 
Cree Health Board, Chisasibi, QC 
CSSSR, Chibougamou, QC 
Val d’Or Hospital, Val d’Or, QC 
Melville Hospital, Goose Bay, NL 
Newfoundland Public Health Laboratory, St. John’s, NL 
Public Health Yukon Communicable Disease Control, Whitehorse, YK Health Protection Unit, Government of NWT, Yellowknife, NT 
JA Hildes Northern Medical Unit, Winnipeg, MB 
Régie Régionale de la Santé et des Services Sociaux, Kuujjuaq, QC 
Région Cri de la Baie James, Module de Santé Publique, Montreal, 
QC 
Communicable Disease Control, Health Laborador Corporation, 
Goose Bay, NL 







Department of Bacteriology, Swedish Institute for Infectious Disease 
Control, Stockholm 






Laboratories Frederikstad, Østf. SSH Sarpsborg SH 
Akershus SSH, SiA 
Bœrum SH 
Aker SH 
Fürsts laborat, Oslo 






Ullevål SH, mik.lab. 
Lab. klin. mikrob. Oslo 
Lillehammer mik.lab 
Elverum mik.lab. 
Buskerud SSH, mik.lab. 
Vestfold SSH, mik.lab. 
Telelab 
Vest-Agder SSH, mik.lab. 
Rogaland SSH, mik.lab. 
Haukeland SH, mik.lab. 
Sogn-Fk. SSH, mik.lab. 
Ålesund FSH, mik.lab. 
Molde FSH, mik.lab. 
Trondheim RSH, mik.lab. 
Innherred SH, mik.lab. 
Namdal SH, mik.lab. 
Nordland SSH, mik.lab. 
Tromsø RSH, mik.lab. 









Arctic Investigations Program, National Center for Infectious 
Diseases, Centers for Disease Control and Prevention, Anchorage, AK 
Laboratories Alaska Native Medical Center, Anchorage, AK Alaska Regional Hospital, Anchorage, AK 
Bartlett Regional Hospital, Juneau, AK 
Bassett Army Hospital, Fort Wainwright, AK 
Central Peninsula General Hospital, Soldotna, AK 
Cordova Community Medical Center, Cordova, AK 
Elmendorf Air Force Base Hospital, Anchorage, AK 
Fairbanks Memorial Hospital, Fairbanks, AK 
Kanakanak Hospital, Dillingham, AK 
Ketchikan Regional Hospital, Ketchikan, AK 
Manilaq Medical Center, Kotzebue, AK 
Norton Sound Regional Hospital, Nome, AK 
Petersburg Medical Center, Petersburg, AK 
Providence Alaska Medical Center, Anchorage, AK 
Providence Island Medical Center, Kodiak, AK 
Samuel Simmonds Memorial Hospital, Barrow, AK 
Sitka Community Hospital, Sitka, AK 
South Peninsula Hospital, Homer, AK 
Southeast Area Regional Health Corporation, Sitka, AK 
State Public Health Laboratory, Division of Public Health, 
Department of Health and Social Services, Anchorage, AK 
Valdez Community Hospital, Valdez, AK 
Valley Hospital, Palmer, AK 
Wrangell General Hospital, Wrangell, AK 
Yukon-Kuskokwim Delta Regional Hospital, Bethel, AK 
 
